TriNetX CEO Gadi Lachman Announces Departure After 11 Years of Leadership
After a remarkable 11-year journey, Gadi Lachman, the driving force behind TriNetX, has officially declared his intention to step down from his roles as founder and CEO. This significant announcement was made on January 10, 2025, and marks the beginning of a new chapter for both Lachman and the company he established.
Founded in 2014, TriNetX has grown to become the leading source of real-world data, playing a crucial role in advancing healthcare research and clinical trials globally. Under Lachman's vision and leadership, the platform has amassed data from more than 25 countries and facilitated millions of queries per month. In his own words, Lachman expressed immense gratitude for the support received from employees, clients, and shareholders, stating, "Thanks to the talent and passion of our team, I am extremely confident in the enduring success of TriNetX."
As Lachman transitions out of his operational position on March 31, 2025, he will continue to serve on the board of directors. Additionally, he will act as an advisor to Carlyle, the majority investor in TriNetX. Jeff Margolis, who currently serves as a director, is set to take over as executive chairman through this transitional phase, ensuring continuity in leadership and governance. Margolis praised Lachman's contributions, reflecting on their 11 years of collaboration, and his significant role in shaping TriNetX into a premier global ecosystem for data and evidence in the life sciences and broader healthcare sectors.
Joe Bress, co-head of global health care at Carlyle, highlighted the impressive progress TriNetX has made under Lachman’s disciplined leadership. Bress noted that TriNetX has maintained profitability even during rapid growth phases, a testament to Lachman's strategic guidance. "Gadi has taken the company to an exciting level and is now passing the baton to a new leader to guide the next chapter of growth and success," he remarked.
Throughout this transition, TriNetX reaffirms its commitment to its mission of enhancing global healthcare through the power of real-world data. The board, management team, and employees remain united in their dedication to innovation while upholding the exceptional legacy left by Lachman.
As a trusted network of healthcare organizations and life sciences companies, TriNetX continues to advance research and accelerate the development of novel therapies. With its user-friendly platform compliant with HIPAA, GDPR, and LGPD, the company provides access to an extensive set of de-identified electronic health records. This enables the global community to improve trial design, streamline operations, refine safety signals, and enhance the evidence generation process.
Looking forward, TriNetX aims to further revolutionize healthcare data analytics and continue its critical role in the clinical research landscape.
Founded in 2014, TriNetX has grown to become the leading source of real-world data, playing a crucial role in advancing healthcare research and clinical trials globally. Under Lachman's vision and leadership, the platform has amassed data from more than 25 countries and facilitated millions of queries per month. In his own words, Lachman expressed immense gratitude for the support received from employees, clients, and shareholders, stating, "Thanks to the talent and passion of our team, I am extremely confident in the enduring success of TriNetX."
As Lachman transitions out of his operational position on March 31, 2025, he will continue to serve on the board of directors. Additionally, he will act as an advisor to Carlyle, the majority investor in TriNetX. Jeff Margolis, who currently serves as a director, is set to take over as executive chairman through this transitional phase, ensuring continuity in leadership and governance. Margolis praised Lachman's contributions, reflecting on their 11 years of collaboration, and his significant role in shaping TriNetX into a premier global ecosystem for data and evidence in the life sciences and broader healthcare sectors.
Joe Bress, co-head of global health care at Carlyle, highlighted the impressive progress TriNetX has made under Lachman’s disciplined leadership. Bress noted that TriNetX has maintained profitability even during rapid growth phases, a testament to Lachman's strategic guidance. "Gadi has taken the company to an exciting level and is now passing the baton to a new leader to guide the next chapter of growth and success," he remarked.
Throughout this transition, TriNetX reaffirms its commitment to its mission of enhancing global healthcare through the power of real-world data. The board, management team, and employees remain united in their dedication to innovation while upholding the exceptional legacy left by Lachman.
As a trusted network of healthcare organizations and life sciences companies, TriNetX continues to advance research and accelerate the development of novel therapies. With its user-friendly platform compliant with HIPAA, GDPR, and LGPD, the company provides access to an extensive set of de-identified electronic health records. This enables the global community to improve trial design, streamline operations, refine safety signals, and enhance the evidence generation process.
Looking forward, TriNetX aims to further revolutionize healthcare data analytics and continue its critical role in the clinical research landscape.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.